Vesilute (10mg)

Product Details: Vesilute (10mg)

Vesilute is a lab-synthesized synthetic dipeptide bioregulator composed of the amino acid sequence Glutamic Acid–Aspartic Acid (Glu-Asp), also denoted as ED in single-letter amino acid code. 

It belongs to the Khavinson family of short-chain cytomedine peptide bioregulators, a class of tissue-specific investigational compounds developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson.

As a cytomedine, Vesilute is structurally modeled on peptide sequences isolated from specific organ tissue and is proposed to exhibit organotropic activity.

Preclinical investigational interest in Vesilute centers on its proposed role in chromatin architecture modulation, urogenital smooth muscle regulation, and gene expression dynamics in aging cellular models. 

This compound is supplied exclusively for controlled laboratory and scientific research purposes and is not intended for any other application.

Mechanism of Action

In preclinical and experimental research settings, Vesilute is characterized as an epigenetic gene expression modulator and urogenital tissue-specific cytomedine research tool.

Investigational data from Khavinson et al. propose that short peptides containing the Glu-Asp sequence interact with specific AT-rich DNA motifs,  particularly the ATTT tetranucleotide, within the cell nucleus. 

It may promote chromatin decondensation and shift heterochromatin toward transcriptionally active euchromatin states in aged or dysfunctional cellular models. [Khavinson et al., 2016].

Related preclinical research further associates the ED dipeptide sequence with activation of ribosomal genes through decondensation of densely packed chromatin fibrils.

Additionally, research on the broader cytomedine peptide class, including compounds sharing the ED sequence, associates this dipeptide motif with modulation of pro-inflammatory cytokine expression patterns, including IL-6 and TNF-alpha pathways, in preclinical monocyte/macrophage cell line studies. [Avolio et al., 2022].

Section	Details
CAS Number	3918-84-1
Molar Mass	262.22 g/mol
Chemical Formula	C₉H₁₄N₂O₇
Synonyms	H-Glu-Asp-OH; Glu-Asp; ED dipeptide; alpha-glutamylaspartic acid; L-α-Glutamyl-L-aspartic acid
Classification	Dipeptide Bioregulator / Khavinson Cytomedine
Ingredients / Composition	≥98.8% (independent third-party analytical testing, HPLC verified)
Shelf Life	2 years
Storage Instructions	Store as lyophilized powder at –18 °C or below, protected from light and moisture
Regulatory Status	Research Use Only (RUO). Not approved by the FDA for use outside controlled laboratory settings.

Research Applications of Vesilute (10mg)

Urogenital Tissue Gene Expression Research 

Vesilute is utilized in laboratory settings to investigate chromatin remodeling dynamics in urinary bladder and prostate tissue cellular models. It may also be applied to explore ATTT DNA motif binding interactions, heterochromatin-to-euchromatin transition mechanisms, and downstream gene expression reactivation patterns in aging urogenital cell systems under controlled in vitro conditions.

Epigenetic and Chromatin Architecture Research 

Utilized in controlled experimental settings to study short-chain peptide interactions with DNA regulatory sequences, ribosomal gene activation through chromatin decondensation, and age-associated transcriptional silencing reversal mechanisms in cellular aging research models.

Cytomedine Cytokine Modulation Research 

Preclinical findings associate Khavinson-class peptides sharing the ED sequence with modulation of IL-6 and TNF-alpha cytokine expression pathways. Vesilute may serve as an investigational research tool for analyzing pro- and anti-inflammatory cytokine balance regulation and neuroimmune signaling network interactions in controlled preclinical in vitro research settings.

Short-Chain Peptide Bioregulator Pharmacokinetic Studies 

Used in controlled laboratory environments to study the cellular penetration dynamics of minimally structured dipeptides, comparative tissue-specificity profiles relative to longer cytomedine compounds such as Prostamax (Lys-Glu-Asp-Pro), and DNA–peptide binding interaction kinetics within the Khavinson bioregulator peptide class.

Why Choose BehemothLabz to Buy Vesilute (10mg)?

BehemothLabz is committed to providing high-purity research peptides manufactured under strict quality control standards. Each batch of Vesilute undergoes independent third-party analytical testing to confirm identity, purity, and consistency.

With a focus on transparency and scientific reliability, BehemothLabz supports researchers with dependable compounds suitable for advanced laboratory and preclinical investigations. Competitive pricing, secure payment processing, and domestic and international shipping availability further support researchers at every level.

Support is direct: support@behemothlabz.com | (307) 429-0990

Disclaimer

This compound is not approved by the U.S. Food and Drug Administration (FDA) for any purpose. It is provided strictly for laboratory and scientific research purposes only. Clinical research initiatives must be conducted under IRB guidance; preclinical studies must comply with IACUC directives under the Animal Welfare Act (AWA). Not for any form of administration outside of controlled laboratory research settings.

Please make sure you review the Terms and Conditions and familiarize yourself with them prior to purchasing. Please research the scientific uses of this product before placing any orders. Please note that the packaging and labels of the product may differ from those shown on the website.

FAQs

Is Vesilute legal in the United States? 

Vesilute is a research chemical not approved by the FDA for use outside of controlled laboratory settings. It is not approved for human or veterinary administration under any circumstances.

What is Vesilute, and what is it investigated for in preclinical research? 

Vesilute is a synthetic Glu-Asp dipeptide bioregulator belonging to the Khavinson cytomedine peptide family. In preclinical research settings, it is investigated for its proposed interactions with chromatin architecture in urogenital tissue cellular models, smooth muscle contractility modulation in urinary bladder experimental systems, and gene expression regulation in aging cell models under controlled laboratory conditions.

What signaling mechanisms is Vesilute associated with in preclinical data? 

Preclinical investigational data associate Vesilute with chromatin decondensation through interaction with AT-rich ATTT DNA motifs, proposed downstream reactivation of transcriptionally silenced genes in aged cellular models, glycogen aggregation inhibition in detrusor smooth muscle cells, calcium signaling attenuation in urinary bladder tissue, and modulation of pro-inflammatory cytokine expression patterns, including IL-6 and TNF-alpha pathways in controlled in vitro research settings.

What are the storage and handling requirements for Vesilute? 

Vesilute is supplied as a lyophilized powder. Store at –20°C or below, protected from light and moisture. Reconstitute using bacteriostatic water under sterile aseptic laboratory conditions. Once reconstituted, aliquot immediately to minimize freeze-thaw degradation and do not store the reconstituted solution at ambient temperature. Researchers are advised to consult the applicable Safety Data Sheet (SDS) prior to handling.

Is Vesilute listed on the WADA Prohibited List? 

Vesilute (H-Glu-Asp-OH, CAS 3918-84-1) is not currently listed on the WADA Prohibited List. Researchers working in sport-adjacent research contexts should verify current status via GlobalDRO.com prior to use, as prohibited list classifications are subject to annual revision. Vesilute is supplied exclusively for controlled laboratory research and is not approved for human or veterinary use under any circumstance. 

Reference Links

Khavinson, V. Kh., Lin’kova, N. S., & Tarnovskaya, S. I. (2016). Short peptides regulate gene expression. Bulletin of Experimental Biology and Medicine, 162(2), 288–292. https://pubmed.ncbi.nlm.nih.gov/27909961/

Ilina, A., Khavinson, V., Linkova, N., & Petukhov, M. (2022). Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer’s disease. International Journal of Molecular Sciences, 23(8), 4259. https://pubmed.ncbi.nlm.nih.gov/35457077/

Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., Mironova, E., Pulcini, R., Robuffo, I., Bologna, G., Simeone, P., Lanuti, P., Guarnieri, S., Trofimova, S., Procopio, A. D., & Toniato, E. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. International Journal of Molecular Sciences, 23(7), 3607. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999041/

Khavinson, V. Kh., Lezhava, T. A., & Malinin, V. V. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1), 78–81. https://pubmed.ncbi.nlm.nih.gov/15085253/